DNA : 3.09 (-4.33%) Why Shares of Ginkgo Bioworks Bounded Higher This Week Motley Fool - Fri Sep 30, 3:32PM CDT. We design custom organisms for customers across multiple markets. Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock analysis from Seeking Alpha's top analysts: exclusive research and insights from bulls and bears. Ginkgo Bioworks has 200 employees, and the revenue per employee ratio is $26,250. Some Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shareholders may be a little concerned to see that the Founder, Bartholomew Canton, recently sold a substantial US$1.1m worth of stock at a price of. Ginkgo Bioworks Holdings Inc is building a platform to enable customers to program cells as easily to program computers. This is an Ark Invest (Cathie Wood) portfolio name. Ginkgo Bioworks Hldgs fundamentals help investors to digest information that contributes to Ginkgo Bioworks' financial success or failures. The development comes fresh on the heels of Ginkgo acquiring adaptive laboratory evolution (ALE) platform provider Altar and horizontal cell programming platform provider Circularis. Ginkgo Bioworks (DNA) specializes in discovering molecules, processes, or strains with commercial value. BOSTON, Oct. 11, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal . The fundamental analysis module provides a way to measure Ginkgo Bioworks' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the . They are . Analysts expect adjusted earnings to reach $-1.235 per share for the current fiscal year. commentary and analysis in pharma and . With its shares popping by more than 21% in a day in the aftermath of its latest earnings report, Ginkgo Bioworks ( DNA -4.33%) is a hot biotech company that's ripe for investment. In other words, Ginkgo is a biology engineering company. Company Profile DNA. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. Massachusetts-based Ginkgo Bioworks opened its wallet Tuesday and snapped up Circularis and Altar to strengthen its cell and gene therapy programs and bolster its manufacturing capabilities.. Financial terms of both deals were not disclosed. Our bioengineers make use of an in-house automated foundry for designing and building new organisms. Its last market close was $14.41 - an increase of 11.79% over the previous week. Merck and Ginkgo Bioworks plan to "engineer up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient ( API) manufacturing efforts." In other words, Merck is tapping. Determine whether Ginkgo Bioworks grew or shrank during the last recession. boston, sept. 9, 2021 /prnewswire/ -- ginkgo bioworks ("ginkgo"), which is building the leading horizontal platform for cell programming, today announced the launch of verb biotics ("verb"), a. Ginkgo Bioworks Holdings Insider Transactions Over The Last Year In fact, the recent sale by Bartholomew Canton was the biggest sale of Ginkgo Bioworks Holdings shares made by an insider individual in the last twelve months, according to our records. The analytics used are: The Moving Average is the average price of the security or contact for the Period shown. The offering may comprise Class A common stock, preferred . On average, analysts rate DNA stock as a buy. 5 minutes The Ginkgo Bioworks (NYSE: DNA) stock price plummeted 20% shortly after activist short-seller Scorpion Capital released a brief report denouncing the company as a "colossal scam". . Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. According to analysts' consensus price target of $8.69, Ginkgo Bioworks has a forecasted upside of 206.1% from its current price of $2.84. Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company: Latest Headlines for Ginkgo Bioworks Holdings Inc. Ginkgo Bioworks Acquires Circularis to Strengthen Capabilities in Cell and Gene Therapy - Oct 4th, 2022 11:01 am . Shares opened at $11.15 apiece under ticker. Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. Ginkgo also expects to integrate several ongoing epidemiological analysis projects and a team of epidemiological data experts into its biosecurity and public health initiative, Concentric by Ginkgo. Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Circularis, a biotechnology company with a proprietary circular RNA . A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. Ginkgo Bioworks Reports Second Quarter 2022 Financial Results News provided by Ginkgo Bioworks Aug 15, 2022, 16:01 ET $145 million of Total revenue in Q2 2022, representing 231% growth over Q2 2021. Sequencing DNA at scale, commonly known as Next Generation Sequencing (NGS), enables Ginkgo Bioworks to sequence thousands of samples per day, and is central to Concentric, Ginkgo Bioworks' COVID-19 . Ginkgo Introduction. Ginkgo Bioworks was founded in the year 2009 by Reshma P. Shetty and Tom Knight. Oh you really wanted to skip straight to our analysis? The funding could value the company at up to $4.8 billion, per a PitchBook estimate, up from a previous valuation of $1.375 billion reached in late 2017. The software, automation and data analysis pipelines we leverage in the Foundry drive a strong scale economic: we have scaled the output of the Foundry by . View the FULL LIST: 2020 DISRUPTOR 50. Ginkgo Bioworks is the organism company. After extensive research and analysis, Zippia's data science team found the following key financial metrics. Analyst Consensus: Buy Analyst Ratings The company recently reported that it has 187.61 million shares sold short, which is 25.02% of all . Ginkgo Bioworks Hldgs Inc (DNA) The Technical Analysis page contains the results of 12 common technical analytics over different periods of time. Currently, Ginkgo Bioworks Holdings Inc's price-earnings ratio is . Baktus, through its subsidiary, Metabiota, Inc., has built an extensive database of infectious disease outbreaks. Learn more . Ginkgo Bioworks employs 641 staff and has a trailing 12-month revenue of around $539.1 million. After reporting. Ginkgo helps drugmakers, consumer brands, and agricultural companies develop specialized microbes.. The Boston genetic engineering company Ginkgo Bioworks and its CEO, Jason Kelly, have been spectacularly successful selling a story: that synthetic biology will transform the manufacture of. So we know that an insider sold shares at around the present share price of US$2.89. Find the average price target, expert sentiment, charts & stats. The Stock rose vividly during the last session to $3.25 after opening rate of $3.14 while the lowest price it went was recorded $3.07 before closing at $3.23.Recently in News on October 4, 2022, Ginkgo Bioworks Acquires . In the last 20 days, the company's Stochastic %K was 60.84% and its Stochastic %D was recorded 51.56%. Ginkgo is constructing, editing, and redesigning the living world in order to answer the globe's growing challenges in health, energy, food, materials, and more. The Ginkgo Bioworks stock price fell by -6.47% on the last day (Monday, 10th Oct 2022) from $3.09 to $2.89. Ginkgo Bioworks ( NYSE: DNA) is a leading synthetic biology company that went public through a SPAC in 2021. Ginkgo Bioworks ( NYSE: DNA) shares dropped over 3% premarket on Wednesday after the company filed for a $500M mixed securities offering. Ginkgo Bioworks is a biotechnology business based in the US. Ginkgo Bioworks peak revenue was $5.3M in 2021. Create real-time notifications to follow any changes in the live stock price. Ginkgo Bioworks Holdings Inc DNA Stock Analysis Morningstar Rating | Rating as of Aug 29, 2022 Quote Chart Stock Analysis News Price vs Fair Value Sustainability Trailing Returns Financials. See Top Rated MarketRank Stocks Here About Ginkgo Bioworks (NYSE:DNA) Stock With modular and customizable sensor solutions, FREDsense is moving analytical lab analysis into the field empowering water utilities, environmental consulting firms and heavy industry to start . Ginkgo expects to meet or exceed its key 2021 targets for the commencement of new cell programs and revenue from its cell programming and biosecurity offerings. Ginkgo's Concentric subsidiary will collaborate with Rwandan public health institutions on technology implementation, training, and data analysis. On January 12, 2022, Ginkgo Bioworks announced preliminary 2021 performance updates. Ginkgo Bioworks (NYSE: DNA ), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Altar, a French biotechnology company that has . Organisms are designed, engineered, developed, tested, and licenced by it. The lowest target is $ 3.03 and the highest is $ 15.23. Followers of the short-selling, investigative-based Scorpion Capital would have witnessed a flash sell-off earlier, attacking Ginko Bioworks for its dubious . The company's platform is market . Get a free in-depth analysis of Ginkgo Bioworks Holdings (DNA) stock. Investment banks generally get a single digit percentage underwriting fee on gross IPO proceeds. Our mission is to make biology easier to engineer. BOSTON, Oct. 4, 2022 /PRNewswire/ Ginkgo Bioworks ( NYSE: DNA ), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Circularis, a biotechnology company with a proprietary circular RNA and promoter screening platform. For roughly $83 million, it will get not only the site, but also the team, as well as the internal. Ginkgo Bioworks, a synthetic-biology company, is going public Friday via a $15 billion SPAC deal. Ginkgo's financial quarter was headlined by $168.4 million in revenue to significantly outpace the Raymond James projection of $95.1 million and the consensus forecast of $105.7 million, while . Ginkgo's mission is to make biology easier to engineer, so the ability to read the DNA of the organisms that we engineer at scale is critical to the success of our mission. The summary of Ginkgo Bioworks Holdings, Inc is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. 2) The Right Shoulder price target would be around $12-$12.25 using the . That also includes engineering organisms to create customer value. According to 12 stock analysts, the average 12-month stock price forecast for DNA stock is $ 8.14 , which predicts an increase of 163.43%. During the last trading day the stock fluctuated 14.71% from a day low at $2.72 to a day high of $3.12. Introduction. Amount of Analyst Coverage Ginkgo Bioworks has only been the subject of 2 research reports in the past 90 days. Courtesy of Ginkgo Bioworks . These "cell programs" are designed to enable biological production of products as diverse as novel therapeutics, key food ingredients, and chemicals currently derived from petroleum. Company. Raw Stochastic average of Ginkgo Bioworks Holdings Inc. in the period of last 50 days is set at 25.00%. The company wants to build a platform for cell programming. . View our latest analysis for Ginkgo Bioworks Holdings earnings-and-revenue-growth Taking into account the latest results, Ginkgo Bioworks Holdings' eight analysts currently expect revenues in 2022. Ginkgo Bioworks CEO Jason Kelly sat down with CNBC's Morgan Brennan on 'Squawk on the Street' to explain what their company does, a peak at their financials and exploring potential growth. View today's Ginkgo Bioworks Holdings stock price and latest DNA news and analysis. Year-over-year quarterly sales growth most recently was 231.7%. <p>FREDsense Technologies Corp, a next generation water quality platform company leveraging synthetic biology to build field kits for faster, cheaper, and more efficient analysis, and Ginkgo Bioworks the leading horizontal platform for cell programming, today announced a partnership to build biosensors for water quality monitoring and detection.</p> Headquartered in Boston, Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. Quick Analysis on Ginkgo Bioworks Holdings, Inc. (DNA) on a 4H Linear Chart. NEW YORK - Ginkgo Bioworks said on Thursday that it has signed a memorandum of understanding with the Rwandan government on biosecurity development and implementation.. See a free in-depth analysis of DNA stock, including forecasts from trusted sources. Ginkgo Bioworks Holdings Inc's trailing 12-month revenue is $539.1 million with a -549.4% profit margin. We use our platform to program cells on behalf of our customers. Ginkgo Bioworks Holdings's DNA short percent of float has fallen 8.12% since its last report. This is useful in estimating the financial strength and credit risk of the company. Anna Marie Wagner, senior vice president of corporate development at Ginkgo Bioworks, told BioSpace that the company is . Will Gornall, a professor at the University of British Columbia business school, believes . Ginkgo to engineer key biocatalytic enzymes for potential use in Merck's drug manufacturing processes . On that day, Ginkgo Bioworks Holdings, Inc. is projected to report earnings of -$0.06 per share, which would represent year-over-year growth of 14.29%. It has now fallen 5 days in a row. DNA technical analysis Your technical analysis summary for Ginkgo Bioworks Holdings, Inc This gauge displays a real-time technical analysis overview for your selected timeframe. Company is doing business in biological engineering goods and bespoke microorganisms are being developed for a variety of markets. This synbio stock was on the ARK funds' shopping list this week. Let's start up with the current stock price of Ginkgo Bioworks Holdings Inc. (DNA), which is $3.09 to be very precise. Ginkgo Bioworks stocks (DNA.US) are listed on the NYSE and all prices are listed in US Dollars. Find Ginkgo Bioworks Holdings Smart Score, expert sentiment, charts & stats. They are SPACs The Wall Street trend which offers an IPO pathway that is slightly less than the usual analysis of a company's financial forecasts. On Monday two ARK funds acquired shares of Ginkgo Bioworks; the ARK Genomic Revolution ETF bought 404,329 shares and the ARK Innovation ETF bought 1,026,000 shares. The buying spree continued into . Ginkgo Bioworks revenue is $5.3M annually. Shares of Ginkgo Bioworks (NYSE: DNA) were down 3.6% at $2.78 today, despite the company announcing a deal with US pharma giant Merck & Co (NYSE: MRK) to engineer a crucial component of up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient (API) manufacturing efforts. Ginkgo Bioworks is seeking to raise up to $311.6 million in Series E funding, PitchBook has learned. October 04, 2022. Ginkgo Bioworks was started in 2009 by a team of MIT scientists intent on building made-to-order microbes that enable customers to grow rather than . We use our platform to program cells on behalf of our customers. Business Description. As part of the SPAC deal, DNA raised over $1.6 billion in proceeds while the S1 shows that SPAC sponsor Eagle Equity owned 43 million shares or over $500 million of stock. Timestamp is: 09:25Ginkgo Bioworks is pretty much our favorite company in biotech right now. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux . We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology. Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Circularis, a biotechnology company with a proprietary circular RNA . These are the largest companies by . Our most recent consensus estimate is calling for quarterly revenue of $50.65 million, down 34.74% from the year-ago period. The price has fallen in 6 of the last 10 days but is still up by 3.21% over the past 2 weeks. For example, a 9-period moving average is the average of the closing prices for the . Ginkgo is building the industry-standard horizontal platform for cell programming. Ginkgo is unique in that we run thousands of tiny samples whereas most infrastructure works on dozens of human genome size samples at a time. Peak Revenue $5.3M (2021) Number of Employees 200 Revenue / Employee 1) The stock price for DNA looks to be potentially forming a Head and Shoulders Pattern with the current Right Shoulder formation in process. GINKGO BIOWORKS HOLDINGS, INC. . Ginkgo Bioworks sees 2021 revenue above guidance. A competitive analysis shows these companies are in the same general field as Ginkgo Bioworks, even though they may not compete head-to-head. The Smart Score is a quantitative, data-driven rating system and does not include human intervention. This has important implications for workflow orchestration, where spending seconds orchestrating tasks is a small time investment compared to the hours each analysis may take. These "cell programs" are designed to enable biological production of products as diverse as novel therapeutics, key food ingredients, and chemicals currently derived from petroleum. Ginkgo Bioworks stock is volatile in the early trade today after the company proposed a securities offering of up to $500 million.The company may offer the securities in either the same or in separate offerings. CALGARY, Canada and BOSTON, April 13, 2022 /PRNewswire/ FREDsense Technologies Corp, a next generation water quality platform company leveraging synthetic biology to build field kits for faster, cheaper, and more efficient analysis, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a .